Slingshot members are tracking this event:

Merck Receives Positive CHMP Opinion for ZEPATIER (elbasvir and grazoprevir) in the European Union

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
MRK Community voting in process

Additional Information

Additional Relevant Details
“We are pleased with the CHMP’s positive opinion recommending the marketing authorization of ZEPATIER in the European Union, which marks an important step forward in the European regulatory process,” said Dr. Roy Baynes, senior vice president and head of clinical development, Merck Research Laboratories. “Our application was based on the findings from a broad clinical development program evaluating the efficacy and safety of ZEPATIER across diverse populations of patients with chronic hepatitis C, including patients with compensated cirrhosis and those with stage 4 or 5 chronic kidney disease.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 27, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Zepatier, Elbasvir, Grazoprevir